Twelve Months 2025 Financial and Business Highlights
- Total twelve-month revenues of
$11.1 million - Healthcare revenues of
$10 million in 2025 - Net income from operations of
$326,000 Net Cash of$5.7 million
Management Commentary
“We saw our 2025 revenues drop slightly when we compare to our 2024 revenues as our clients delt with the volatility and uncertainty of the current economy,” remarked
“We have expanded our investment in AI products, announced our AI strategy and are steadily launching new AI based solutions,” said
Financial Review for the twelve Months Ended
Total revenues for the twelve months ended
The company reported a net income for the twelve months of approximately
The company finished the year with approximately
Detailed financial information may be downloaded at www.liveworld.com/ir or at https://www.otcmarkets.com/stock/LVWD/overview.
About
LiveWorld is a Human-Led, AI-Powered digital marketing agency and software company. We unlock the full potential of social and digital media to transform customer relationships through integrated compliance, engagement, and insight solutions.
Purpose-built for highly regulated healthcare and pharma brands, LiveWorld combines proactive compliance, expert-led social media moderation, dynamic community engagement, and AI-powered insights to help brands listen smarter, engage more meaningfully, and act with confidence. Our approach blends human expertise with advanced AI to deliver genuine human connections, ensure accuracy, safety, and relevance, turning real-world conversations into trusted intelligence and measurable business impact.
LiveWorld clients include the number one brands in pharmaceuticals, healthcare, and financial-travel services. LiveWorld is headquartered in
“Safe Harbor" Statement Under The Private Securities Litigation Reform Act
This press release may contain forward-looking information concerning
LiveWorld Contacts
IR Contact:
dhouston@liveworld.com
(408) 615-8496
PR Contact:
mhammer@liveworld.com
(737) 212-9739
| UNAUDITED CONDENSED BALANCE SHEETS | |||||||
| (In thousands, except share data) | |||||||
| 2025 | 2024 | ||||||
| ASSETS | |||||||
| Current assets | |||||||
| Cash and cash equivalent | $ | 7,313 | $ | 6,603 | |||
| Accounts receivable, net | 1,309 | 682 | |||||
| Prepaid expenses | 246 | 290 | |||||
| Total current assets | 8,868 | 7,575 | |||||
| Property and equipment, net | 18 | 33 | |||||
| Other assets | 27 | 27 | |||||
| Total assets | $ | 8,913 | $ | 7,635 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 242 | $ | 182 | |||
| Accrued employee expenses | 595 | 1,068 | |||||
| Other accrued liabilities | 1,555 | 413 | |||||
| Deferred revenue | 761 | 860 | |||||
| Total current liabilities | 3,153 | 2,523 | |||||
| Total liabilities | 3,153 | 2,523 | |||||
| Stockholders' equity | |||||||
| Common stock: 45,633,442 issued and outstanding as of | 34 | 34 | |||||
| Additional paid-in capital | 144,773 | 144,451 | |||||
| Accumulated deficit | (139,047 | ) | (139,373 | ) | |||
| Total stockholders' equity | 5,760 | 5,112 | |||||
| Total liabilities and stockholders' equity | $ | 8,913 | $ | 7,635 | |||
| CONDENSED STATEMENT OF OPERATIONS | |||||
| (In thousands, except per share data) | |||||
| Twelve Months Ended | |||||
| 2025 | 2024 | ||||
| Total revenues | $ | 11,140 | $ | 11,348 | |
| Cost of revenues | 5,404 | 6,023 | |||
| Gross Margin | 5,736 | 5,325 | |||
| Operating Expense | |||||
| Product development | 1,336 | 1,048 | |||
| Sales and marketing | 1,630 | 1,554 | |||
| General and administrative | 2,504 | 2,634 | |||
| Total operating expense | 5,470 | 5,236 | |||
| Income from operations | 266 | 89 | |||
| Income before tax | 266 | 89 | |||
| Other Income | 88 | 5 | |||
| Provision for income taxes | 28 | 25 | |||
| Net income from operations | 326 | 69 | |||
| Earnings per share analysis from operations: | |||||
| Basic income per share | $ | 0.01 | $ | 0.00 | |
| Shares used in computing basic loss per share | 45,633,442 | 45,633,442 | |||
| Diluted net income (loss) per share | $ | 0.01 | $ | 0.00 | |
| Shares used in computing diluted income (loss) per share | 54,992,049 | 56,350,862 | |||
| Departmental allocation of stock-based compensation: | |||||
| Cost of revenues | $ | 81 | $ | 80 | |
| Product development | 21 | 18 | |||
| Sales and marketing | 31 | 33 | |||
| General and administrative | 188 | 189 | |||
| Total stock-based compensation | $ | 321 | $ | 320 | |
| CONDENSED STATEMENTS OF CASH FLOWS | |||||||
| (In thousands) | |||||||
| Twelve Months Ended | |||||||
| 2025 | 2024 | ||||||
| Cash flows from operating activities: | |||||||
| Net income (loss) | $ | 326 | $ | 69 | |||
| Adjustments to reconcile net income (loss) provided by (used in) operating activities: | |||||||
| Depreciation of long-lived assets | 21 | 26 | |||||
| Stock-based compensation | 321 | 320 | |||||
| Changes in operating assets and liabilities: | |||||||
| Accounts receivable | (627 | ) | 1,019 | ||||
| Other assets | 47 | (66 | ) | ||||
| Accounts payable | 60 | (56 | ) | ||||
| Accrued liabilities | 668 | 249 | |||||
| Deferred revenue | (100 | ) | 422 | ||||
| Net cash provided by (used in) operating activities | 716 | 1,983 | |||||
| Cash flows from investing activities: | |||||||
| Purchase of property and equipment | (6 | ) | (15 | ) | |||
| Net cash provided by (used in) investing activities | (6 | ) | (15 | ) | |||
| Cash flows from financing activities: | |||||||
| Proceeds from exercise of stock options | ----- | ---- | |||||
| Net cash provided by (used for) financing activities | ----- | ---- | |||||
| Change in cash and cash equivalent | 710 | 1,968 | |||||
| Cash and cash equivalents, beginning of period | 6,603 | 4,635 | |||||
| Cash and cash equivalents, end of period | $ | 7,313 | $ | 6,603 | |||
| Supplemental disclosure of non-cash financing and investing activities: | |||||||
| Income tax paid | $ | 28 | $ | 25 | |||
Source: 